Effect of the focal adhesion kinase inhibitor TAE226 on the epithelial-mesenchymal transition in human oral squamous cell carcinoma cell line

doi:10.7518/hxkq.2020.01.004

Abstract

Abstract:

Objective To study the effect of the focal adhesion kinase inhibitor TAE226 on epithelial-mesenchymal transition (EMT) in human oral squamous cell carcinoma (OSCC) cell line. Methods HSC-3 and HSC-4 cells were cultured with TAE226 under different concentrations (0, 1, 5, and 10 μmol·L^-1) for 24, 48, and 72 h. Real-time quantitative polymerase chain reaction was performed to detect the mRNA expressions of E-cadherin and Vimentin. The protein expressions of E-cadherin and Vimentin were determined by Western blot assay after 48 h of TAE226 treatment. Results Real-time quantitative polymerase chain reaction showed that increasing the TAE226 dose and reaction time resulted in increased and decreased E-cadherin and Vimentin mRNA expressions, respectively (P<0.05). Western blot assays showed that increasing the TAE226 dose resulted in increased and decreased E-cadherin and Vimentin protein expressions, respectively (P<0.05). Conclusion TAE226, which is expected to be an effective drug for OSCC treatment, can effectively inhibit the EMT of the OSCC cell line.

Key words: focal adhesion kinase inhibitor TAE226, epithelial-mesenchymal transition, oral squamous cell carcinoma

CLC Number:

R739.8

Zou Xiangyu,Zeng Qin,Liu Ping,Nie Minhai. Effect of the focal adhesion kinase inhibitor TAE226 on the epithelial-mesenchymal transition in human oral squamous cell carcinoma cell line[J]. West China Journal of Stomatology, 2020, 38(1): 17-22.

Figures/Tables 10

Tab 1

Fig 1

Tab 2

Tab 3

Tab 4

Tab 5

Fig 2

Fig 3

Tab 6

Tab 7

References 22

[1]	Rustad KC, Wong VW, Gurtner GC . The role of focal adhesion complexes in fibroblast mechanotransduction during scar formation[J]. Differentiation, 2013,86(3):87-91.
[2]	Wang YJ, Zhang ZF, Fan SH , et al. MicroRNA-433 inhibits oral squamous cell carcinoma cells by targeting FAK[J]. Oncotarget, 2017,8(59):100227-100241.
[3]	Otani H, Yamamoto H, Takaoka M , et al. TAE226, a bis-anilino pyrimidine compound, inhibits the EGFR-mutant kinase including T790M mutant to show anti-tumor effect on EGFR-mutant non-small cell lung cancer cells[J]. PLoS One, 2015,10(6):e0129838.
[4]	Sathiyasekar AC, Chandrasekar P, Pakash A , et al. Overview of immunology of oral squamous cell carcinoma[J]. J Pharm Bioallied Sci, 2016,8(Suppl 1):S8-S12.
[5]	Çankaya H, Güneri P, Epstein JB . Adjunctive methods and devices for clinical detection of oral squamous cell carcinoma[J]. Oral Health Prev Dent, 2015,13(1):29-39.
[6]	Zhang MX, Zheng SS, Jing CY , et al. S100A11 promotes TGF-β1-induced epithelial-mesenchymal transition through SMAD2/3 signaling pathway in intrahepatic cholangiocarcinoma[J]. Future Oncol, 2018,14(9):837-847.
[7]	Lamouille S, Xu J, Derynck R . Molecular mechanisms of epithelial-mesenchymal transition[J]. Nat Rev Mol Cell Biol, 2014,15(3):178-196.
[8]	Goñi GM, Epifano C, Boskovic J , et al. Phosphatidylinositol 4,5-bisphosphate triggers activation of focal adhesion kinase by inducing clustering and conformational changes[J]. Proc Natl Acad Sci USA, 2014,111(31):E3177-E3186.
[9]	Lietha D, Eck MJ . Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation[J]. PLoS One, 2008,3(11):e3800.
[10]	Hehlgans S, Lange I, Eke I , et al. 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226[J]. Radiother Oncol, 2009,92(3):371-378.
[11]	Kurio N, Shimo T, Fukazawa T , et al. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo[J]. Exp Cell Res, 2011,317(8):1134-1146.
[12]	Attramadal CG, Kumar S, Boysen ME , et al. Tumor budding, EMT and cancer stem cells in T1-2/N0 oral squamous cell carcinomas[J]. Anticancer Res, 2015,35(11):6111-6120.
[13]	Natsuizaka M, Whelan KA, Kagawa S , et al. Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma[J]. Nat Commun, 2017,8(1):1758.
[14]	Palen K, Weber J, Dwinell MB , et al. E-cadherin re-expression shows in vivo evidence for mesenchymal to epithelial transition in clonal metastatic breast tumor cells[J]. Oncotarget, 2016,7(28):43363-43375.
[15]	Hermiston ML, Wong MH, Gordon JI . Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for nonautonomous regulation of cell fate in a self-renewing system.[J]. Genes Dev, 1996,10(8):985-996.
[16]	Perl AK, Wilgenbus P, Dahl U , et al. A causal role for E-cadherin in the transition from adenoma to carcinoma[J]. Nature, 1998,392(6672):190-193.
[17]	Zhou WH, Gong L, Wu QC , et al. Correction to: PHF8 upregulation contributes to autophagic degradation of E-cadherin, epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2018. doi. 10.1186/s13046-018-0944-7.
[18]	Murakami M, Imabayashi K, Watanabe A , et al. Identification of novel function of vimentin for quality standard for regenerated pulp tissue[J]. J Endod, 2012,38(7):920-926.
[19]	Li LF, Wei ZJ, Sun H , et al. Abnormal β-catenin immunohistochemical expression as a prognostic factor in gastric cancer: a meta-analysis[J]. World J Gastroenterol, 2014,20(34):12313-12321.
[20]	Schultze A, Decker S, Otten J , et al. TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis[J]. Invest New Drugs, 2010,28(6):825-833.
[21]	Kurio N, Shimo T, Fukazawa T , et al. Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma[J]. Oral Oncol, 2012,48(11):1159-1170.
[22]	Jones RJ, Brunton VG, Frame MC . Adhesion-linked kinases in cancer, emphasis on Src, focal adhesion kinase and PI 3-kinase[J]. Eur J Cancer, 2000,36(13):1595-1606.

引物名称	引物序列（5’- 3’）	片段大小/bp
GAPDH	F- GACAGTCAGCCGCATCTTCT	395
	R- AAATGAGCCCCAGCCTTCTC
E-cadherin	F- GAGTGCCAACTGGACCATTCAGTA	106
	R- AGTCACCCACCTCTAAGGCCATC
Vimentin	F- CTCTCAAAGATGCCCAGGAG	176
	R- GCACGATCCAACTCTTCCTC

TAE226浓度/	作用时间
μmol·L^-1	24 h	48 h	72 h
0	1.00±0.25^aA	1.01±0.10^aA	0.80±0.13^bA
1	1.98±0.66^aB	3.77±0.34^bB	6.41±0.16^cB
5	4.15±0.02^aC	8.08±0.12^bC	14.52±0.97^cC
10	10.10±0.84^aD	11.18±0.09^bD	20.58±0.32^cD

TAE226浓度/	作用时间
μmol·L^-1	24 h	48 h	72 h
0	1.01±0.18^aA	1.61±0.12^bA	3.16±0.97^cA
1	0.90±0.13^aB	0.75±0.06^bB	0.55±0.21^cB
5	0.76±0.44^aC	0.51±0.03^bC	0.15±0.29^cC
10	0.25±0.18^aD	0.11±0.05^bD	0.08±0.00^cD

TAE226浓度/	作用时间
μmol·L^-1	24 h	48 h	72 h
0	1.01±0.18^aA	0.71±0.09^bA	0.68±0.08^cA
1	1.40±0.10^aB	3.20±0.36^bB	10.01±0.29^cB
5	2.15±0.50^aC	11.42±1.22^bC	23.65±1.07^cC
10	3.70±0.34^aD	16.68±0.53^bD	27.08±1.02^cD

TAE226浓度/	作用时间
μmol·L^-1	24 h	48 h	72 h
0	0.98±0.10^aA	1.87±0.38^bA	3.22±0.65^cA
1	0.97±0.32^aA	0.73±0.68^bB	0.45±0.17^cB
5	0.75±0.27^aB	0.41±0.07^bC	0.20±0.09^cC
10	0.45±0.21^aC	0.07±0.20^bD	0.04±0.01^cD